Literature DB >> 26120541

Th22 cells in allergic disease.

Kilian Eyerich1, Stefanie Eyerich2.   

Abstract

During the last decade, the field of T cell immunology started to confuse the scientific community. More and more subtypes of T helper cells and their counterparts in the innate immune system are described. We are just at the beginning to understand which specific function the distinct subtypes fulfill. Th22 cells are terminally differentiated and very specialized T helper cells characterized by the secretion of their signature cytokine IL-22 and lack of IL-4, IL-17 and IFN-γ. The main function of Th22 cells is to protect epithelial barrier organs such as skin and lung, but also to modulate inflamed and injured tissue. This review summarizes our current knowledge on Th22 cells and their function in allergic disease. Cite this as Eyerich K, Eyerich S. Th22 cells in allergic disease. Allergo J Int 2015;24:1-7 DOI: 10.1007/s40629-015-0039-3.

Entities:  

Keywords:  IL-22; T cell; T helper cell; Th22; allergy; atopic eczema

Year:  2015        PMID: 26120541      PMCID: PMC4479457          DOI: 10.1007/s40629-015-0039-3

Source DB:  PubMed          Journal:  Allergo J Int        ISSN: 2197-0378


Definition of lymphocytes: a more and more confusing field

Since the eighties, our knowledge on T helper cells increased tremendously. The ongoing description of new T helper (Th) cells and innate lymphocyte populations (ILC), however, further increase the confusion in the field as commonly used classification schemes seem to be antiquated, redundant or insufficient. Therefore, it is reasonable to elaborate on the definition of T helper cells before discussing the function of Th22 cells in allergic disease. The first classification scheme was suggested by Mosmann and Coffmann at the end of the eighties. Here, two T helper subtypes were distinguished according to their expressed signature cytokines – Th1 cells secreting interferon (IFN)-γ and Th2 secreting interleukin (IL)-4 [1]. Already at this time it was assumed that an additional population of T cells should exist that is able to limit the inflammatory effects of Th1 and Th2 cells in tissue. These cells were originally named T suppressor cells, however, only after description of the transcription factor Fox p 3 and the more attractive naming as regulatory T cells (Treg), these cells were commonly accepted. Some years after the discovery of IL-17 in 1993 [2], and the description of Th1 and Th2 cells co-secreting IL-17 [3, 4], another T cell subtype specifically secreting IL-17 has been identified. Several studies elucidated that these cells represent an additional lineage in the family of T helper cells and were named according to their signature cytokine as Th17 cells [5]. Being qualified as new lineage goes along with the differentiation of naive T cells into effector T cells in presence of a specific cytokine environment (in case of Th17 cell TGF-β, IL-1β and IL-6) and the expression of a characteristic transcription factor (in case of Th17 cells RORC; ROR: “RAR-related orphan receptor“). IL-22 was described in 2000 [6] and first regarded a Th1 cytokine [5]. However, with growing knowledge on Th17 cells, IL-22 was consequently associated with this T helper subtype. The phenomenon that some T helper cells secrete more than one signature cytokine is called plasticity. By generation of this concept, the problem in the historical grouping of T helper cells according to the expression of single cytokines was solved. Nowadays, it is widely accepted that Th1, Th2 and Th17 cells exist that co-secrete IL-22. In addition, a subgroup of T helper cells did not express the signature cytokines IFN-γ, IL-4 and IL-17, but IL-22 solely. These cells were described in 2009 for the first time of three research groups and named Th22 cells [7, 8, 9]. Meanwhile, some alternative suggestions for classification of lymphocytes appeared on the scene that take the function (e. g., follicular T helper cells) or chemokine receptor profile into account. This format of this review is not suited to discuss all the existing classification schemes. Therefore, just a summarized personal appreciation: Until now, no concept exists that classifies lymphocytes into subtypes convincingly. Furthermore, our knowledge on lymphocytes from innate immunity (ILC) – lymphocytes without a functional T cell receptor and not belonging to adaptive immunity – is steadily growing. Due to lacking and convincing concepts, also ILC are classified according to their cytokine profile [10]. But we are positive that research in the field will deliver new and reliable concepts. Tab. 1 gives and overview on known T cell subtypes secreting IL-22.
Tab. 1

Cellular source of IL-22* (modified according to [5] and [63])

cell additional secreted factors development transcription factor surface marker
adaptive immunity
Th17 [44]IL-17IL-21IL-26TNF-α(IL-10)CCL20differentiation: naive T cell plus TGF-β/IL-1β/IL-6 [45, 46];amplification: IL-21 [47];stability: IL-23 [48]RORCCD4+ CCR4+ CCR6+ CXCR3- CD161+ IL-23R+ [49, 50]
Th22 [9, 51]TNF-αIL-13(IL-10)FGF(?)naive T cell plus TNF-α/IL-6AHR(?)CD4+ CCR4+ CCR6+ CCR10+ PDGFR+
Th1/IL-22IFN-γTNF-α(IL-10)unknown
Th2/IL-22IL-4IL-5IL-13IL-22(IL-10)unknown
CD8+ T cell [52] murine: CD8+ T cell plus TGF-β/IL-6 [53]/IL-1β/IL-23 [54] murine: RORγtCD3+ CD8+ CD45RO+
T follicular helper cell [55]IL-21naive T cell plus + IL-21 + IL-6 + ICOSL [56]unknown (BCL6? [57])CD4+ ICOS+ CXCR5+
innate immunity
ILC1IFN-γID2+ precursor cell (?)TbetLIN-CD56+NKp46+NKp30+NKp44+IL-7Rα murine: LIN-Thy1+SCA1+
ILC1 - NKIFN-γ, TNFID2+ precursor cell (?)Tbet, EomesCD122+NKG2D+CD161+KIR+ murine: NKp46+NK1.1+CD122+NKG2D+ CD161+CD16+CD11b+
ILC2IL-5, IL-9, IL-13, IL-4ID2+ precursor cell (?)GATA3LIN-IL-7Rα+CD45hiCD161+CRTH2 murine: LIN-ICOS+SCA1+IL-7Rα+
ILC3 [10]IFN-γ, TNFID-2+ precursor cell (?)ID-2 (?)LIN−CD56+NKp46+NKp30+NKp44+ IL-7Rα+murine: LIN-NKp46+
Lti (to ILC3) [59]IL-5, IL-9, IL-13, IL-4unknown (NK cell?)RORC, AHRLIN-IL-7RαhiCD45int murine: NKp46-
NKT [58]IL-17, IL-22LT-α, LT-βlymphoid precursor cellRORCD3+ CD56+ CD161+ CD16+
γδT-cell [60]IL-17IFN-γnaive T cellCD3+CD4+γδTCR+ murine: CD3+ CD4-CD8- CD27- [61] CD25+ CD122- [62]

*If not marked explicitly as “murine“, the table summarizes human data.

AHR, aryl-hydrocarbon-receptor; IFN, interferon; IL, interleukin; ILC, innate lymhhoid cells; Lti, lymphoid-tissue inducer; PDGF, platelet-derived growth factor; ROR, RAR-related orphan receptors; TGF, transforming growth factor; Th, T helper cell; TNF, tumor necrosis factor

Cellular source of IL-22* (modified according to [5] and [63]) *If not marked explicitly as “murine“, the table summarizes human data. AHR, aryl-hydrocarbon-receptor; IFN, interferon; IL, interleukin; ILC, innate lymhhoid cells; Lti, lymphoid-tissue inducer; PDGF, platelet-derived growth factor; ROR, RAR-related orphan receptors; TGF, transforming growth factor; Th, T helper cell; TNF, tumor necrosis factor Starting with this pessimistic attitude, it is questionable if Th22 cells can be really defined as separate lineage. Two reasons argue for it: Th22 cells represent the extreme of a spectrum of IL-22 secreting cells and, importantly, Th22 cells are characterized by a combination of cytokines that in their totality have essential function in tissue. This function will be elucidated in more detail in the next section.

Definition and phenotype of Th22 cells

Th22 cells differentiate, like other T helper cells, from naive precursor cells. The specific microenvironment for generation of Th22 is composed of tumornecrosis factor (TNF)-β and IL-6 [8] (Fig. 1). Also skin dendritic cells have been shown to play an essential role in this differentiation process [8, 11]. Once differentiated, the phenotype of Th22 cells remains stable over many weeks in culture and is not skewable into another phenotype [7]. This argues for Th22 cells being terminally differentiated effector cells. The aryl-hydrocarbon-receptor (AHR) was suggested as transcription factor [9], however, it is not exclusively expressed in Th22 cells and does not explain all pattern of the Th22 phenotype. Th22 cells are characterized by expression of the chemokine receptors CCR4 and CCR4 and more characteristic CCR10 [8]. Chemokines that bind to these receptors are strongly expressed in the skin. This explains the abundance of Th22 cells in tissue and their low numbers in circulation. In the skin, Th22 cells are guided into the upper parts of the epidermis due to production of the CCR10 ligand CCL27 by keratinocytes [7, 12].
Fig. 1

Phenotype of Th22 cells. Shown is differentiation from naive T cells under influence of TNF-β and IL-6, the putative transcription factor Ahr, the surface profile and secreted cytokines.

Phenotype of Th22 cells. Shown is differentiation from naive T cells under influence of TNF-β and IL-6, the putative transcription factor Ahr, the surface profile and secreted cytokines. To evaluate the function of a T helper cell in tissue with a special focus on allergic disease, some more parameters next to migratory capacity or homing have to be defined: the expression of functional surface proteins, secreted mediators and the mechanisms of activation with respect to their antigen-specificity. Next to the above mentioned chemokine receptors, Th22 cells express all typical markers for T helper cells such as CD3 and CD4 [7]. More characteristic is the high expression of platelet-derived growth factor (PDGF) receptors [7]. The functional relevance of this receptor is not known, yet. Molecules involved in induction of apoptosis such as Fas and TRAIL are weakly expressed in Th22 cells [13] and consequently, the closely related CD8+ T22 cells (Tc22 cells) have a lower capacity to induce apoptosis compared to their IL-22 negative counterparts [14, 15]. As already mentioned, Th22 cells do not secrete signature cytokines of Th2-, Th2-, or Th17 cells. However, Th22 cells co-secrete little amounts of IL-13 and TNF-β [7]. On gene expression level, Th22 have been shown to express a bunch of fibroblast growth factors (FGF) [7]. Until now, it has not been investigated if FGF are secreted in functionally relevant amounts.

IL-22: a many-sided cytokine

The overall phenotype of Th22 cells points to a per se protective role in tissue, in particular the skin. This is represented especially by the function of IL-22 itself (Fig. 2). IL-22 binds to a heterodimeric receptor consisting of the IL-10Rβ and the IL-22RA chain. While the IL-22 receptor (IL-22R) is strongly and abundantly expressed on epithelial cells, immune cells lack IL-22R [16]. Therefore, Th22 cells form an important link between adaptive immunity and barrier organs leading to their functional attribute being “tissue signaling leukocytes” [5]. By binding to its receptor, IL-22 induces proliferation and migration of the target cell and simultaneously inhibits differentiation and reactivity to apoptosis [17, 18, 19]. A combination of these effects builds the basis for efficient wound healing reactions. Indeed, it could have been shown that Th22 cells are important players in wound healing reactions [7, 20]. This per se positive attribute can turn pathologic if regulatory mechanisms are missing. Too much of IL-22 effects can lead to a psoriatic phenotype with over activated metabolism in keratinocytes resulting in acanthosis and hyperkeratosis [21]. In addition, under some circumstances it might be not useful to protect an epithelial cell from apoptosis, especially in case of (pre)-malignancies and intracellular infections. In line with this, it has been reported that Th22 cells have negative effects on gastrointestinal tumors [22, 23]. In tumors, the protective function of IL-22 is additionally reinforced through a direct antagonism with IFN-γ, a known inducer of apoptosis and tumor senescence [14, 24]. Therefore exact regulation of IL-22 is of outermost importance and happens mainly via a soluble antagonist, the IL-22 binding protein (IL-22BP) [25].
Fig. 2

Function of IL-22 in dependence of the local microenvironment. Per se IL-22 induces proliferation and migration in epithelial cells and inhibits differentiation and reactivity to apoptosis (middle); these effect are inhibited by IFN-γ (left). Together with TNF-β and IL-17 strong innate immune reactions in epithelial cells are induced (right).

Function of IL-22 in dependence of the local microenvironment. Per se IL-22 induces proliferation and migration in epithelial cells and inhibits differentiation and reactivity to apoptosis (middle); these effect are inhibited by IFN-γ (left). Together with TNF-β and IL-17 strong innate immune reactions in epithelial cells are induced (right). Besides its protective effects on epithelial cells, IL-22 plays an important role in the induction of innate immune responses at barrier organs. A binding of IL-22 to the IL-22R weakly induces the expression of anti-microbial peptides such as S100 proteins and defensins (e.g. HBD-2) [7, 16]. More impressive, however, is the amplifying impact on cytokines that induce innate immunity in epithelial cells. Here, IL-22 clearly synergizes with IL-17 [26] and TNF-α [27] with functional relevance in the defense against pathogens for instance Candida albicans. Patients suffering from the rare disease chronic mucocutaneous candidiasis (CMC) represent a dramatic example. Due to different reasons, CMC patients are not able to express IL-17 and IL-22 leading to severe and persistent infections of skin and mucosa with Candida species [28, 29]. One recommendation at the end of the section. It is not possible to judge on the overall function of Th22 cells without careful consideration of the local microenvironment.

Th22 cells in context of allergic diseases

According to the exclusive expression of the IL-22R in tissue, Th22 cells do interact directly with epithelial cells but do not influence the memory of adaptive immunity in response to allergens. Another essential argument against a direct contribution of Th22 cells to allergic disease is the observation that neither Th17 nor Th22 cells show an allergen reactivity in cell culture models of atopic eczema (AE) or allergic contact dermatitis (ACD) for the relevant allergen or hapten [13, 30]. In fact, both T helper subtypes specifically recognize extracellular microorganisms such as Staphylococci and Candida species or auto-antigens that are presented via CD1 molecules [31, 32, 33]. Fitting to this fact, IL-17 and IL-22 are induced in T cells by enterotoxins of staphylococci [30, 34]. Even if Th22 do not primarily induce immune reactions against allergens or haptens, they are relevant for allergic reactions in the skin in an indirect way. Most patients with AE are colonized permanently with Staphylococcus aureus [35, 36]. The number of IL22 producing cells in AE skin is quite high, also in comparison with other inflammatory skin diseases such as psoriasis. Although many more IL-22 producing Th17 cells are present in psoriasis lesions, the number of IL-22 secreting cells in total is the same in both diseases [37, 38]. This is due to a considerably elevated proportion of Th22 cells in AE [39]. Th22 or Tc22 seem to be of relevance in the chronic state of AE [40]. Actually, for Tc22 a correlation with severity of AE was shown [39]. Therefore, it is likely that Th22 cells act as allergen-independent modulators in inflamed tissue and are involved in remodeling processes during chronification. Similar results have been obtained in models of asthma bronchiale. Here, IL-22 is mediating remodeling in tissue and contributes to transition of disease from active into the chronic state [14, 41]. However, in the early phase of asthmatic inflammation, Th22 seem to have rather positive and tissue-protective effects [14, 42]. Data on a potential role of Th22 cells in allergic Typ-1 reactions such as anaphylaxis, mastocytosis or urticaria do hardly exist. Interestingly, it is speculated about an interaction of IL-22+ cells and mast cells in tissue and that this close proximity of both cell types leads to induction of Th22 cells via mast cells [43]. In conclusion, the demand on motivated allergy researchers in the field of Th22 cells is not covered, yet!
  62 in total

1.  Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production.

Authors:  Hideki Fujita; Kristine E Nograles; Toyoko Kikuchi; Juana Gonzalez; John A Carucci; James G Krueger
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-08       Impact factor: 11.205

2.  A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist.

Authors:  W Xu; S R Presnell; J Parrish-Novak; W Kindsvogel; S Jaspers; Z Chen; S R Dillon; Z Gao; T Gilbert; K Madden; S Schlutsmeyer; L Yao; T E Whitmore; Y Chandrasekher; F J Grant; M Maurer; L Jelinek; H Storey; T Brender; A Hammond; S Topouzis; C H Clegg; D C Foster
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

Review 3.  Th17 cells: critical mediators of host responses to burn injury and sepsis.

Authors:  Juan L Rendon; Mashkoor A Choudhry
Journal:  J Leukoc Biol       Date:  2012-06-29       Impact factor: 4.962

4.  IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha.

Authors:  C Albanesi; A Cavani; G Girolomoni
Journal:  J Immunol       Date:  1999-01-01       Impact factor: 5.422

5.  Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells.

Authors:  Eva V Acosta-Rodriguez; Laura Rivino; Jens Geginat; David Jarrossay; Marco Gattorno; Antonio Lanzavecchia; Federica Sallusto; Giorgio Napolitani
Journal:  Nat Immunol       Date:  2007-05-07       Impact factor: 25.606

6.  Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling.

Authors:  Stefanie Eyerich; Kilian Eyerich; Davide Pennino; Teresa Carbone; Francesca Nasorri; Sabatino Pallotta; Francesca Cianfarani; Teresa Odorisio; Claudia Traidl-Hoffmann; Heidrun Behrendt; Stephen R Durham; Carsten B Schmidt-Weber; Andrea Cavani
Journal:  J Clin Invest       Date:  2009-11-16       Impact factor: 14.808

7.  Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis.

Authors:  Julia K Gittler; Avner Shemer; Mayte Suárez-Fariñas; Judilyn Fuentes-Duculan; Kara J Gulewicz; Claire Q F Wang; Hiroshi Mitsui; Irma Cardinale; Cristina de Guzman Strong; James G Krueger; Emma Guttman-Yassky
Journal:  J Allergy Clin Immunol       Date:  2012-08-27       Impact factor: 10.793

8.  Human mast cells drive memory CD4+ T cells toward an inflammatory IL-22+ phenotype.

Authors:  Nicolas Gaudenzio; Camille Laurent; Salvatore Valitutti; Eric Espinosa
Journal:  J Allergy Clin Immunol       Date:  2013-03-19       Impact factor: 10.793

9.  CD1a-autoreactive T cells are a normal component of the human αβ T cell repertoire.

Authors:  Annemieke de Jong; Victor Peña-Cruz; Tan-Yun Cheng; Rachael A Clark; Ildiko Van Rhijn; D Branch Moody
Journal:  Nat Immunol       Date:  2010-10-31       Impact factor: 25.606

10.  A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis.

Authors:  Caroline Sutton; Corinna Brereton; Brian Keogh; Kingston H G Mills; Ed C Lavelle
Journal:  J Exp Med       Date:  2006-07-03       Impact factor: 14.307

View more
  11 in total

Review 1.  T regulatory (Treg) and T helper 17 (Th17) lymphocytes in thyroid autoimmunity.

Authors:  Roberto González-Amaro; Mónica Marazuela
Journal:  Endocrine       Date:  2015-10-16       Impact factor: 3.633

2.  Interleukin-4 and interferon-γ orchestrate an epithelial polarization in the airways.

Authors:  U M Zissler; A M Chaker; R Effner; M Ulrich; F Guerth; G Piontek; K Dietz; M Regn; B Knapp; F J Theis; H Heine; K Suttner; C B Schmidt-Weber
Journal:  Mucosal Immunol       Date:  2015-11-18       Impact factor: 7.313

3.  Tape strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin.

Authors:  Ana B Pavel; Yael Renert-Yuval; Jianni Wu; Ester Del Duca; Aisleen Diaz; Rachel Lefferdink; Milie M Fang; Talia Canter; Stephanie M Rangel; Ning Zhang; James G Krueger; Amy S Paller; Emma Guttman-Yassky
Journal:  Allergy       Date:  2020-08-20       Impact factor: 14.710

4.  Ambient particulate matter enhances the pulmonary allergic immune response to house dust mite in a BALB/c mouse model by augmenting Th2- and Th17-immune responses.

Authors:  Alejandro R Castañeda; Christoph F A Vogel; Keith J Bein; Heather K Hughes; Suzette Smiley-Jewell; Kent E Pinkerton
Journal:  Physiol Rep       Date:  2018-09

5.  Role of IL-22 in persistent allergic airway diseases caused by house dust mite: a pilot study.

Authors:  Laura Tamasauskiene; Vilte Marija Gintauskiene; Daina Bastyte; Brigita Sitkauskiene
Journal:  BMC Pulm Med       Date:  2021-01-21       Impact factor: 3.317

6.  Derma-Hc, a New Developed Herbal Formula, Ameliorates Cutaneous Lichenification in Atopic Dermatitis.

Authors:  Yeon Kyung Nam; Mi Hye Kim; In Jin Ha; Woong Mo Yang
Journal:  Int J Mol Sci       Date:  2021-02-26       Impact factor: 5.923

7.  The Pathogenic Roles of IL-22 in Colitis: Its Transcription Regulation by Musculin in T Helper Subsets and Innate Lymphoid Cells.

Authors:  Jun Yan; Jing Yu; Ke Liu; Yijia Liu; Changchuin Mao; Wenda Gao
Journal:  Front Immunol       Date:  2021-12-21       Impact factor: 7.561

8.  Systemic and local cytokine profile and risk factors for persistent allergic airway inflammation in patients sensitised to house dust mite allergens.

Authors:  Laura Tamasauskiene; Brigita Sitkauskiene
Journal:  BMC Pulm Med       Date:  2021-12-21       Impact factor: 3.317

Review 9.  Role of Th17 Cytokines in Airway Remodeling in Asthma and Therapy Perspectives.

Authors:  Victor Margelidon-Cozzolino; Anne Tsicopoulos; Cécile Chenivesse; Patricia de Nadai
Journal:  Front Allergy       Date:  2022-02-02

10.  Enhanced Type 2 Immune Reactions by Increased IL-22/IL-22Ra1 Signaling in Chronic Rhinosinusitis With Nasal Polyps.

Authors:  Dong Kyu Kim; Ara Jo; Hee Suk Lim; Jin Youp Kim; Kyoung Mi Eun; Jayoung Oh; Joon Kon Kim; Seong Ho Cho; Dae Woo Kim
Journal:  Allergy Asthma Immunol Res       Date:  2020-11       Impact factor: 5.764

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.